A 5-year Longitudinal Observational Study of Patients Undergoing
Therapy for IMISC (TARGET-DERM)
ID# NCT03661866
Recruitment Status: Recruiting
Estimated Study Completion Date: December 31, 2026
HS Connect listed this: October 2020
Sponsor: Target PharmaSolutions, Inc.
Information provided by (Responsible Party): Target PharmaSolutions, Inc.
Brief Summary:
TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Please link for complete trial details:
https://clinicaltrials.gov/ct2/show/NCT03661866
Location:
Multiple US locations. Please see link provided above for all location details and to confirm your location is recruiting.
Contact Information:
Contact: Laura Dalfonso Phone: 9842340268
Email: ldalfonso@targetpharmasolutions.com
Laura Malahias Phone: 9842340268 ext 209